Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Common Equity: 2010-2024

Historic Common Equity for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $7.7 million.

  • China Pharma Holdings' Common Equity rose 27.35% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 27.35%. This contributed to the annual value of $7.7 million for FY2024, which is 3.93% up from last year.
  • Per China Pharma Holdings' latest filing, its Common Equity stood at $7.7 million for FY2024, which was up 3.93% from $7.5 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Common Equity registered a high of $8.0 million during FY2020, and its lowest value of $4.3 million during FY2022.
  • For the 3-year period, China Pharma Holdings' Common Equity averaged around $6.5 million, with its median value being $7.5 million (2023).
  • As far as peak fluctuations go, China Pharma Holdings' Common Equity dropped by 28.71% in 2022, and later soared by 73.77% in 2023.
  • China Pharma Holdings' Common Equity (Yearly) stood at $8.0 million in 2020, then declined by 24.82% to $6.0 million in 2021, then decreased by 28.71% to $4.3 million in 2022, then skyrocketed by 73.77% to $7.5 million in 2023, then increased by 3.93% to $7.7 million in 2024.